• Mean future costs after a false negative diagnosis can range from 7,644 € (Minimum 2,555; Maximum 22,993) at a disease prevalence of 10% (cycle 1) to 3,129 € (Minimum 2,555; Maximum 3,832) at a disease prevalence of 90% (cycle 9) in the patient population (Table 1 ).
• Sensitivity and specificity value calculations have meanwhile been confirmed by several, independent study results 2,3 , comparing CE to intraoperative endoscopy, which is close to be regarded as gold standard.
RESULTS

OBJECTIVES Model Input Values
• Assumptions for pretest probability, sensitivity, specificity and variations with Monte Carlo methods are a useful technique to evaluate the cost-effectiveness of diagnostic tests if a gold standard is not available routinely.
• Break down of pre-diagnostic resource consumption into cycles imitates situation in patient populations and is more appropriate than calculation with mean values.
• CE used as an example for this method gives a good guidance to place it in the diagnostic pathway for obscure gastrointestinal bleeding. • Prevalence dependent ICE reveals cost saving potential of CE when used at a prevalence of 10% or higher. This corresponds with application of CE after negative upper and lower gastroscopy (Figure 1 ).
CONCLUSIONS
• Greatest savings are observed for a prevalence rate of 50%. At higher prevalences -i.e. at a later stage in the diagnostic path -cost savings decrease due to increase of false positive diagnoses. Sensitivity:
• Per patient, location in small intestine only 
